Eight-year experience in treating aggressive mediastinal large B-cell lymphomas
- Authors: Mangasarova I.K1, Magomedova AU1, Kravchenko SK1, Shmakov RG2, Bariakh EA1, Vorob'ev VI1, Mar'in DS1, Skidan NI1, Gemdzhian ÉG1, Misiurin AV3, Kremenetskaia AM1, Vorob'ev AI1
-
Affiliations:
- Гематологический научный центр Минздрава России
- Научный центр акушерства, гинекологии и перинатологии им. акад. В.И. Кулакова Минздрава России
- Федеральный научно-клинический центр детской гематологии, онкологии и иммунологии им. Дмитрия Рогачева Минздрава России, Москва
- Issue: Vol 85, No 7 (2013)
- Pages: 50-56
- Section: Editorial
- URL: https://journals.rcsi.science/0040-3660/article/view/31299
- ID: 31299
Cite item
Full Text
Abstract
Full Text
##article.viewOnOriginalSite##About the authors
Ia K Mangasarova
Гематологический научный центр Минздрава России
Email: v.k.jana@mail.ru
125167 Москва, Новый Зыковский пр-д, д. 4а
A U Magomedova
Гематологический научный центр Минздрава России
Email: maminat@mail.ru
S K Kravchenko
Гематологический научный центр Минздрава России
Email: krav@blood.ru
R G Shmakov
Научный центр акушерства, гинекологии и перинатологии им. акад. В.И. Кулакова Минздрава России
Email: mdshmakov@mail.ru
E A Bariakh
Гематологический научный центр Минздрава России
Email: ebaryakh@gmail.com
V I Vorob'ev
Гематологический научный центр Минздрава России
Email: morela@mail.ru
D S Mar'in
Гематологический научный центр Минздрава России
Email: dmdoc@mail.ru
N I Skidan
Гематологический научный центр Минздрава России
Email: nskidan@rambler.ru
É G Gemdzhian
Гематологический научный центр Минздрава России
Email: edstat@mail.ru
A V Misiurin
Федеральный научно-клинический центр детской гематологии, онкологии и иммунологии им. Дмитрия Рогачева Минздрава России, Москва
Email: cyclone@nm.ru
A M Kremenetskaia
Гематологический научный центр Минздрава России
Email: mtkalexandra@gmail.ru
A I Vorob'ev
Гематологический научный центр Минздрава России
Email: mtkalexandra@gmail.ru
References
- Friedberg J.W., Fisher R.I. Diffuse large B cell lymphoma. Hematol Oncol Clin North Am 2008; 22: 941-952.
- Lichtenstein A.K., Levine A., Taylor C.R. et al. Primary mediastinal lymphoma in adults. Am J Med 1980; 68: 509-514.
- Lenz G., Staudt L.M. Mechanisms of disease aggressive lymphomas. N Engl J Med 2010; 362: 1417-1429.
- Ковригина А.М., Пробатова Н.А. Лимфома Ходжкина и крупноклеточные лимфомы. М: МИА 2007: 108-124.
- Isaacson P.G., Norton A.J., Addis B.J. The human thymus contains a novel population of B lymphocytes. Lancet 1987; 2: 1488-1491.
- Copie-Bergman C., Gaulard P., Maouche-Chretien L. et al. The MAL Gene Is Expressed in Primary Mediastinal Large B-Cell Lymphoma. Blood 2009; 94: 3567-3575.
- Monti S., Savage K., Kutok J. Molecular profiling of diffuse large B-cell lymphoma identifies robust subtypes including one characterized by host inflammatory response. Blood 2005; 105: 1851-1861.
- Iqbal J., Greiner T., Patel K. et al. Distinctive patterns of BCL6 molecular alterations and their functional consequences in different subgroups of diffuse large B-cell lymphoma. Leukemia 2007; 21: 2332-2343.
- Huang J., Sanger G., Greiner T. et al. The t(14;18) defines a unique subset of large B-cell lymphoma with a germinal center B-cell gene expression profile. Blood 2002; 99 (7): 2285-2290.
- Rosenwald A., Wright G., Leroy K. et al. Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. J Exp Med 2003; 198: 851-862.
- Savage K.J., Monti S., Kutok J.L. et al. The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma. Blood 2008; 102: 3871-3879.
- Bentz M., Barth T.F., Bruderlein S. et al. Gain of chromosome arm 9p Is characteristic of primary mediastinal B-cell lymphoma (MBL): comprehensive molecular cytogenetic analysis and presentation of a novel MBL cell line. Genes, Chromosomes & Cancer 2001; 30: 393-340.
- Melzner I., Bucur A.J., Bruderlein S. et al. Biallelic mutation of SOCS-1 impairs JAK2 degradation and sustains phospho-JAK2 action in the MedB-1 mediastinal lymphoma line. Blood 2005; 105: 2535-2542.
- Ding B.B., Yu J.J., Yu R.Y. et al. Constitutively activated STAT3 promotes cell proliferation and survival in the activated B-cell subtype of diffuse large B-cell lymphomas. Blood 2008; 111: 1515-1523.
- Freeman G.J., Long A.J., Iwai Y. et al. Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation. J Exp Med 2000; 192: 1027-1034.
- Latchman Y., Wood C.R., Chernova T. et al. PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nat Immunol 2001; 2: 261-268.
- Savage K.J., Monti S., Kutok J.L. et al. The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma. Blood 2008; 102: 3871-3879.
- Rodig S.J., Savage K.J., Nguyen V. et al. TRAF1 and c-REL activation are useful adjuncts in distinguishing classical Hodgkin Lymphoma from a subset of morphologically or immunophenotypically similar lymphomas. Am J Surg Pathol 2005; 29: 196-203.
- Мангасарова Я.К., Мисюрин А.В., Магомедова А.У. и др. Молекулярная диагностика первичной медиастинальной В-клеточной лимфомы и диффузной В-крупноклеточной лимфомы с первичным вовлечением лимфатических узлов средостения. Клин онкогематол 2011; 4: 142-145.
- Mangasarova J., Misuyrin A., Magomedova A. et al. Molecular differential diagnosis distinguishes between primary mediastinal B cell lymphoma and diffuse large B cell lymphoma with primary involvement of mediastinal lymph nodes. Blood 2011; 118: 250.
- Dupuis J., Itti E., Rahmouni A. et al. Response assessment after an inductive CHOP or CHOP-like regimen with or without rituximab in 103 patients with diffuse large B-cell lymphoma: integrating 18fluorodeoxyglucose positron emission tomography to the International Workshop Criteria. Ann Oncol 2009; 20: 503-507.
- Pettengell R., Radford J.A., Morgenstern G.R. et al. Survival benefit from high-dose therapy with autologous blood progenitor-cell transplantation in poor-prognosis non-Hodgkin lymphoma. J Clin Oncol 1996; 14: 586-592.
- Магомедова А.У., Кравченко С.К., Кременецкая А.М. и др. Модифицированная программа NHL-BFM-90 в лечении больных диффузной В-крупноклеточной лимфосаркомой. Тер арх 2006; 10: 44-47.
- Hamlin P.A., Portlock C.S., Straus D.J. et al. Primary mediastinal large B-cell lymphoma: optimal therapy and prognostic factor analysis in 141 consecutive patients treated at Memorial Sloan Kettering from 1980 to 1999. BJH 2005; 130 (5): 691-699.
- Zinzani P.L. Stefoni V., Finolezzi E. et al. Rituximab combined with MACOP-B or VACOP-B and radiation therapy in primary mediastinal large B-cell lymphoma: a retrospective study. Clin Lymphoma Myeloma 2009; 9(5): 381-385.
- Rodriguez J., Conde E., Gutierrez A. et al. Primary mediastinal large cell lymphoma (PMBL): frontline treatment with autologous stem cell transplantation (ASCT). The GEL-TAMO experience. Hematol Oncol 2008; 23: 110-115.
- Cairoli R., Grillo G., Tedeschi A. et al. Efficacy of an early intensification treatment integrating chemotherapy, autologous stem cell transplantation and radiotherapy for poor risk primary mediastinal large B cell lymphoma with sclerosis. Bone Marrow Transplant 2002; 29: 473-477.
- Surbone A., Peccatori F., Paulidis N. et al. Cancer and pregnancy. Heidelberrg: Springer-Verlag 2008; 254.
- Cardonick E., Iacobucci A. Use of chemotherapy during human pregnancy. Lancet Oncol 2004; 5: 283-289.
- Cheson B.D., Pfistner B., Juweid M.E. et al. Revised Response Criteria for Malignant Lymphoma. J Clin Oncol 2007; 25: 579-586.
- Rosenwald A., Wright G., Leroy K. et al. Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. J Exp Med 2003; 198: 851-862.
- Friddberg J.W. PET positive, PET negative, PET peeve? Blood 2010; 115 (4): 752-753.
- Moskowitz C.H., Schoder H., Teruya-Feldstein J. et al. Risk-adapted dose-dense immunochemotherapy determined by interim FDG-PET in advanced-stage diffuse large B-cell lymphoma. J Clin Oncol 2010; 28: 1896-1903.
- Terasawa T., Nihashi T., Hotta T. et al. 18F-FDG PET for posttherapy assessment of Hodgkin's disease and aggressive Non-Hodgkin's lymphoma: a systematic review. J Nucl Med 2008; 49: 13-21.
![](/img/style/loading.gif)